lunes, 3 de agosto de 2015

Últimos días. Curso de Perfeccionamiento en Soporte Nutricional

Educación e Investigación

Estimada /o. Atento a su interés en el Curso de Perfeccionamiento en Soporte Nutricional: Nutrición Enteral y Parenteral (7 de agosto), tengo el agrado de dirigirme a Usted a fin de informarle  que aún quedan disponibles las últimas vacantes para formalizar su inscripción en dicha actividad
Para mayor información copio el link donde encontrará todo lo concerniente a dicho Curso:

En caso de estar interesada / o  en inscribirse,  al Curso Perfeccionamiento en Soporte Nutricional  podrá realizarlo online a través del mencionado link o  presentarse en la Secretaría de Posgrado del Instituto Universitario (Potosí 4234  segundo piso Capital Federal), de lunes a viernes de 10  a 13.30 y de 15 a 19 horas  
Sin otro particular y quedando a su disposición
Reciba un cordial saludo,

Víctor Moure
Departamento de Posgrado
IUHIPotosí 4234, C.A.B.A.Tel. (011) 4959-0200 int. 5324

Perfeccionamiento en soporte nutricional:
 nutrición enteral y parenteral

Médicos y Licenciados en Nutrición
Inicia: 7 de agosto de 2015
Finaliza: 4 de junio de 2016
Directores: Dra. Claudia Kecskes | Dr. Edgardo Menéndez | Dra. Débora Setton
Coordinación General: Dra. María de los Angeles Carignano 
Carga Horaria: 150 horas.
Duración: 9 meses
Modalidad: Presencial
Régimen de cursada: Primer fin de semana de cada mes. Viernes de 9.00 a 18.00 horas y sábado de 9.00 a 13.00 horas.

Objetivos generales
• Detectar pacientes en riesgo nutricional mediante la implementación de técnicas de screening.
• Reconocer los mecanismos fisiopatológicos involucrados en las alteraciones metabólicas y nutricionales de distintas enfermedades.
• Interpretar los resultados de los distintos métodos de evaluación nutricional.
• Determinar las metas nutricionales dentro de un plan de soporte nutricional y estimar los requerimientos de macro y micronutrientes.
• Diseñar un plan de soporte nutricional y metabólico de acuerdo con las características de cada una de las patologías estudiadas.
• Conocer los diversos sistemas de administración enterales y parenterales junto con los insumos necesarios para su implementación.
• Prevenir, detectar y tratar complicaciones asociadas con la nutrición enteral y parenteral.
• Utilizar herramientas de organización y gestión de calidad dentro de un programa de soporte nutricional multidisciplinario.

• Screening y evaluación inicial del paciente que requiere nutrición parenteral.
• Nutrición parenteral: indicaciones, formulación.
• Fórmulas parenterales: componentes, clasificación, preparación y administración.
• Monitoreo de la nutrición parenteral.
• Prevención y tratamiento de las complicaciones asociadas a la nutrición parenteral.
• Accesos venosos: tipos, colocación y mantenimiento.
• Técnicas de cuidados de la nutrición parenteral (bolsas, catéteres, sistemas de infusión).
• Nutrición parenteral en patologías específicas I y II.
• Nutrición parenteral domiciliaria.

Potosí 4234, 2do. piso, C.A.B.A.
Lunes a viernes de 9.00 a 13.30hs - 15.30 a 18.00hs.
(011) 4959-0200 Int5324

Autism Care Costs Could Hit $500 Billion by 2025: Study: MedlinePlus

Autism Care Costs Could Hit $500 Billion by 2025: Study: MedlinePlus

MedlinePlus Trusted Health Information for You

Autism Care Costs Could Hit $500 Billion by 2025: Study

Researchers stress need for research to find better interventions, treatments, to lower future spending
By Robert Preidt
Wednesday, July 29, 2015
HealthDay news image
WEDNESDAY, July 29, 2015 (HealthDay News) -- The annual cost of caring for Americans with autism might reach $500 billion by 2025, a new study estimates, with outside estimates approaching $1 trillion.
Health economists at the University of California, Davis, analyzed national data and concluded that costs will range from $162 billion to $367 billion in 2015, with $268 billion being their best estimate.
"The current costs of [autism] are more than double the combined costs of stroke and hypertension, and on a par with the costs of diabetes," study senior author Paul Leigh, a professor of public health sciences and a researcher with the Center for Healthcare Policy and Research at UC Davis, said in a university news release.
By 2025, autism costs will range from $276 billion to $1 trillion, with $461 billion being the researchers' best estimate, according to the study published online July 28 in the Journal of Autism and Developmental Disorders.
The cost estimates include health services, residential care, in-home care, special education, transportation, employment support and lost productivity.
The cost forecasts in the study are based on the assumption that effective interventions and treatments for autism will not be identified or widely available by 2025.
"There should be at least as much public research and government attention [paid] to finding the causes and best treatments for [autism] as there is for these other major diseases," Leigh added.
He stressed the need for significant policy changes that emphasize early intervention to reduce autism symptoms, along with employment and other programs to support independent living for adults with autism.
"This approach would ultimately save money that otherwise would be spent on expensive custodial care," Leigh said.
SOURCE: University of California, Davis, news release, July 28, 2015
More Health News on:
Autism Spectrum Disorder

New Emergency Use Authorizations - Ebola and MERS-CoV

FDA Medical Countermeasures Initiative Update

Emergency Use Authorizations


Ebola treatment center in West Africa, taken July 5, 2014

On July 31, 2015, FDA issued an EUA for the OraQuick® Ebola Rapid Antigen Test for the presumptive detection of Ebola Zaire virus in individuals with signs and symptoms of Ebola virus infection in conjunction with epidemiological risk factors, in laboratories or facilities adequately equipped, trained, and capable of such testing.

This point-of-care test is intended for circumstances when use of a rapid Ebola virus test is determined to be more appropriate than use of an authorized Ebola virus nucleic acid test, which has been demonstrated to be more sensitive in detecting the Ebola Zaire virus.more


On July 17, 2015, FDA issued an EUA to authorize the emergency use of the RealStar® MERS-CoV RT-PCR Kit U.S. for the in vitro qualitative detection of RNA from the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). more

Related information

Image: Ebola treatment center in West Africa, taken in July 2014 (Credit: CDC/Flickr). More aboutCDC's Ebola response efforts.

News updates

  • August 24, 2015: Quality Metrics Public Meeting - The public meeting and draft guidance(PDF, 250 KB) are intended to gain stakeholders’ perspective in various aspects of the development and planned implementation of a quality metrics program launched under the authority of section 704 of the Food, Drug, and Cosmetic Act (FD&C Act). The guidance includes an explanation of CDER and CBER approaches to collecting and using data to aid in ensuring that regulatory review, compliance, and inspection policies are based on state-of-the-art pharmaceutical science and that they support continuous improvement and innovation in the pharmaceutical manufacturing industry.  Register by August 7, 2015Read an FDA Voice blog post about Quality Metrics.
  • September 18, 2015: 2015 FDA Science Writers Symposium - a special event intended to engage and inform science and health journalists about how the FDA is applying scientific approaches to critical public health issues. Registration is free and open to credentialed media; register by September 14, 2015.
  • September 28, 2015: FDA/CDC/NLM Workshop on Promoting Semantic Interoperability of Laboratory Data (Silver Spring, MD and webcast) - The purpose of the workshop is to receive and discuss input from stakeholders regarding proposed approaches to promoting the semantic interoperability of laboratory data between in vitro diagnostic devices and database systems, including laboratory information systems and electronic health records. Register by September 18, 2015.
  • September 29-30, 2015: Public workshop - Medical Device Patient Labeling (Silver Spring, MD and webcast) - register to attend in person or online by September 21, 2015
View more events on the frequently updated MCMi News and Events page
Preparedness and response: 
  • HHS awards improve health care, public health preparedness - Health departments across the country will receive more than $840 million in cooperative agreements from the U.S. Department of Health and Human Services to improve and sustain emergency preparedness of state and local public health and health care systems. (July 6, 2015)
  • HHS has published a Response and Recovery Resources Compendium, a comprehensive web-based repository of HHS resources and capabilities available to Federal, State, local, territorial and tribal stakeholders before, during, and after public health and medical incidents. (July 15, 2015)
  • The White House published a fact sheet on the Global Health Security Agenda. (July 28, 2015)
Federally funded research:
Image: FDA scientist Anjuli Jain conducts an experiment validating nonclinical biomarker models for traumatic brain injury. This research will potentially help establish a regulatory pathway for the use of emerging flexible EEG technologies to rapidly detect brain injury during emergency response situations, such as explosions. (Photo: FDA staff)
Also see Request for Quality Metrics, under Events above
Deadline reminders:
  • CDC is proposing to add certain H5N1 influenza virus strains to the list of HHS select agents and toxins. Comment by September 14, 2015.
  • NIH and CDC are soliciting proposals from small businesses to conduct research and development, including possible medical countermeasure-related research - respond byOctober 16, 2015. 
In case you missed it:
  • FDA is amending its regulations to implement certain drug shortages provisions of the FD&C Act, as amended by the Food and Drug Administration Safety and Innovation Act (FDASIA). The rule requires all applicants of covered approved drugs or biological products—including certain applicants of blood or blood components for transfusion and all manufacturers of covered drugs marketed without an approved application—to notify FDA electronically of a permanent discontinuance or an interruption in manufacturing of the product that is likely to lead to a meaningful disruption in supply (or a significant disruption in supply for blood or blood components) of the product in the United States. (July 8, 2015)

  • Innovation at FDA - These updated web pages outline how FDA is helping to speed treatments and cures to patients. The new section includes news, blog posts, speeches, fact sheets, and reports. (July 2015)